Use of a functional classification of anemia in myelodysplastic syndromes to identify subgroups of patients responsive to recombinant human-erythropoietin therapy

Eur J Haematol. 1996 Jan-Feb;56(1-2):106-8. doi: 10.1111/j.1600-0609.1996.tb00311.x.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anemia / classification*
  • Anemia / drug therapy*
  • Anemia / genetics
  • Biomarkers
  • Erythropoietin / blood
  • Erythropoietin / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Karyotyping
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / classification*
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics
  • Receptors, Transferrin / analysis
  • Recombinant Proteins / therapeutic use

Substances

  • Biomarkers
  • Receptors, Transferrin
  • Recombinant Proteins
  • Erythropoietin